United States · Platforms & data · MarketBeat

Satellos Bioscience Sets Duchenne Trial Endpoint After FDA Talks, Eyes 2027 Results

Published by MarketBeat · United States 1 h ago

Satellos Bioscience (NASDAQ:MSLE) said it will use MRI-measured muscle fat fraction as the primary efficacy endpoint in its Phase II BASECAMP study of forazapadin for boys living…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Telus targets $900M annualized cash savings exiting 2028 while projecting $500M AI infrastructure revenue over 3 years

The Motley Fool

Hims & Hers Health vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy for 2027?

Investing.com

Empery Digital director Tice Brown sells $1,193 in shares

MarketWatch

‘I have no financial safety net’: I’m 66, rely on Social Security and have just $500 in savings. What hope do I have?

CNBC

Nasdaq drops into correction territory — here’s what typically happens next

Yahoo Finance